Canaccord Genuity Starts Exact Sciences (EXAS) at Buy; The Earlier The Better
Tweet
Share
E-mailGet Alerts EXAS Hot Sheet
Price: $104.91 --0%
Rating Summary:
8 Buy, 27 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 6
Rating Summary:
8 Buy, 27 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 6
Join SI Premium – FREE
Canaccord Genuity initiates coverage on Exact Sciences (NASDAQ: EXAS) with a Buy. PT $15.00.
Canaccord analyst, Jeffrey Frelick, said, "Our view of EXAS is underpinned by the company addressing what we believe are the two most important needs for greater compliance toward colorectal cancer (CRC) screening: pre-cancer detection and a highly accurate non-invasive test. We believe EXAS presents a unique, molecular diagnostic approach to colorectal cancer screening that can improve clinical outcomes."
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $8.25 yesterday.
Canaccord analyst, Jeffrey Frelick, said, "Our view of EXAS is underpinned by the company addressing what we believe are the two most important needs for greater compliance toward colorectal cancer (CRC) screening: pre-cancer detection and a highly accurate non-invasive test. We believe EXAS presents a unique, molecular diagnostic approach to colorectal cancer screening that can improve clinical outcomes."
For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.
Shares of Exact Sciences closed at $8.25 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Starts Aditya Birla Real Estate (ABREL:IN) at Buy
- Goldman Sachs Reinstates Etsy (ETSY) at Neutral
- Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
